Neural grafting in Parkinson's disease. Problems and possibilities

Progress in Brain Research

Volumn 184, Issue C, 2010, Pages 265-294

  Brundin, Patrik ^a   Barker, Roger A ^b   Parmar, Malin ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Dopamine neuron; Dyskinesias; Lewy bodies; Parkinson's disease; Stem cells; Transplantation

Indexed keywords

BOOK; CLINICAL TRIAL; DONOR; DOPAMINERGIC NERVE CELL; DYSKINESIA; EMBRYONIC STEM CELL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NERVE CELL; NERVE GRAFT; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PATIENT SELECTION; PRIORITY JOURNAL; STEM CELL; SURGICAL TECHNIQUE; TISSUE PREPARATION; TREATMENT OUTCOME;

EID: 77957230012     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(10)84014-2     Document Type: Chapter

References (172)

1. Allan L.E., Petit G.H., Brundin P. Cell transplantation in Parkinson's disease: Problems and perspectives. Current Opinion in Neurology 2010, 23(4):426-432.
2. Alvarez-Buylla A., Garcia-Verdugo J.M., Tramontin A.D. A unified hypothesis on the lineage of neural stem cells. Nature Reviews Neuroscience 2001, 2(4):287-293.
3. Amariglio N., Hirshberg A., Scheithauer B.W., Cohen Y., Loewenthal R., Trakhtenbrot L., et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Medicine 2009, 6(2):e1000029.
4. Amit M., Carpenter M.K., Inokuma M.S., Chiu C.P., Harris C.P., Waknitz M.A., et al. Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. Developmental Biology 2000, 227(2):271-278.
5. Anderson L., Burnstein R.M., He X., Luce R., Furlong R., Foltynie T., et al. Gene expression changes in long term expanded human neural progenitor cells passaged by chopping lead to loss of neurogenic potential in vivo. Experimental Neurology 2007, 204(2):512-524.
6. Anderson J.P., Walker D.E., Goldstein J.M., de Laat R., Banducci K., Caccavello R.J., et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. Journal of Biological Chemistry 2006, 281(40):29739-29752.
7. Andersson E.K., Irvin D.K., Ahlsio J., Parmar M. Ngn2 and Nurr1 act in synergy to induce midbrain dopaminergic neurons from expanded neural stem and progenitor cells. Experimental Cell Research 2007, 313(6):1172-1180.
8. Andersson E., Tryggvason U., Deng Q., Friling S., Alekseenko Z., Robert B., et al. Identification of intrinsic determinants of midbrain dopamine neurons. Cell 2006, 124(2):393-405.
9. Apostolides C., Sanford E., Hong M., Mendez I. Glial cell line-derived neurotrophic factor improves intrastriatal graft survival of stored dopaminergic cells. Neuroscience 1998, 83(2):363-372.
10. Barker R.A. Continuing trials of GDNF in Parkinson's disease. Lancet Neurology 2006, 5(4):285-286.
11. Barker R., Dunnett S. The biology and behaviour of intracerebral adrenal transplants in animals and man. Reviews Neuroscience 1993, 4(2):113-146.
12. Barker R.A., Widner H. Immune problems in central nervous system cell therapy. NeuroRx 2004, 1(4):472-481.
13. Bjorklund A., Dunnett S.B., Brundin P., Stoessl A.J., Freed C.R., Breeze R.E., et al. Neural transplantation for the treatment of Parkinson's disease. Lancet Neurology 2003, 2(7):437-445.
14. Boer G.J. Ethical guidelines for the use of human embryonic or fetal tissue for experimental and clinical neurotransplantation and research. Network of European CNS Transplantation and Restoration (NECTAR). Journal of Neurology 1994, 242(1):1-13.
15. Bonilla S., Hall A.C., Pinto L., Attardo A., Gotz M., Huttner W.B., et al. Identification of midbrain floor plate radial glia-like cells as dopaminergic progenitors. Glia 2008, 56(8):809-820.
16. Braak H., Ghebremedhin E., Rub U., Bratzke H., Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Research 2004, 318(1):121-134.
17. Bradley A., Evans M., Kaufman M.H., Robertson E. Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines. Nature 1984, 309(5965):255-256.
18. Brederlau A., Correia A.S., Anisimov S.V., Elmi M., Paul G., Roybon L., et al. Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: Effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells 2006, 24(6):1433-1440.
19. Brundin P., Barbin G., Strecker R.E., Isacson O., Prochiantz A., Bjorklund A. Survival and function of dissociated rat dopamine neurones grafted at different developmental stages or after being cultured in vitro. Brain Research 1988, 467(2):233-243.
20. Brundin P., Karlsson J., Emgard M., Schierle G.S., Hansson O., Petersen A., et al. Improving the survival of grafted dopaminergic neurons: A review over current approaches. Cell Transplantation 2000, 9(2):179-195.
21. Brundin P., Li J.Y., Holton J.L., Lindvall O., Revesz T. Research in motion: The enigma of Parkinson's disease pathology spread. Nature Reviews Neuroscience 2008, 9(10):741-745.
22. Brundin P., Melki R., Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nature Reviews Molecular Cell Biology 2010, 11(4):301-307.
23. Brundin P., Petersen A., Hansson O. Graft survival. Journal of Neurosurgery 1999, 90(4):804-806.
24. Brundin P., Pogarell O., Hagell P., Piccini P., Widner H., Schrag A., et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 2000, 123(Pt 7):1380-1390.
25. Buc-Caron M.H. Neuroepithelial progenitor cells explanted from human fetal brain proliferate and differentiate in vitro. Neurobiology of Disease 1995, 2(1):37-47.
26. Buzzard J.J., Gough N.M., Crook J.M., Colman A. Karyotype of human ES cells during extended culture. Nature Biotechnology 2004, 22(4):381-382. author reply 382.
27. Cai J., Donaldson A., Yang M., German M.S., Enikolopov G., Iacovitti L. The role of Lmx1a in the differentiation of human embryonic stem cells into midbrain dopamine neurons in culture and after transplantation into a Parkinson's disease model. Stem Cells 2009, 27(1):220-229.
28. Cai J., Yang M., Poremsky E., Kidd S., Schneider J.S., Iacovitti L. Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA lesioned rats. Stem Cells and Development 2010, 19(7):1017-1023.
29. Caldwell M.A., He X., Wilkie N., Pollack S., Marshall G., Wafford K.A., et al. Growth factors regulate the survival and fate of cells derived from human neurospheres. Nature Biotechnology 2001, 19(5):475-479.
30. Caldwell M.A., Svendsen C.N. Heparin, but not other proteoglycans, potentiates the mitogenic effects of FGF-2 on mesencephalic precursor cells. Experimental Neurology 1998, 152(1):1-10.
31. Carlsson T., Carta M., Winkler C., Bjorklund A., Kirik D. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. Journal of Neuroscience 2007, 27(30):8011-8022.
32. Carlsson T., Winkler C., Lundblad M., Cenci M.A., Bjorklund A., Kirik D. Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiology of Disease 2006, 21(3):657-668.
33. Carta M., Carlsson T., Kirik D., Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007, 130(Pt 7):1819-1833.
34. Carta M., Carlsson T., Munoz A., Kirik D., Bjorklund A. Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease. Movement Disorder 2010, 25(Suppl. 1):S174-S179.
35. Castilho R.F., Hansson O., Brundin P. FK506 and cyclosporin A enhance the survival of cultured and grafted rat embryonic dopamine neurons. Experimental Neurology 2000, 164(1):94-101.
36. Chambers S.M., Fasano C.A., Papapetrou E.P., Tomishima M., Sadelain M., Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nature Biotechnology 2009, 27(3):275-280.
37. Christophersen N.S., Brundin P. Large stem cell grafts could lead to erroneous interpretations of behavioral results?. Nature Medicine 2007, 13(2):118. ; author reply 118-119.
38. Chu Y., Kordower J.H. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?. Neurobiology of Disease 2007, 25(1):134-149.
39. Chu Y., Kordower J.H. Lewy body pathology in fetal grafts. Annals of the New York Academy of Sciences 2010, 1184:55-67.
40. Chung S., Shin B.S., Hwang M., Lardaro T., Kang U.J., Isacson O., et al. Neural precursors derived from embryonic stem cells, but not those from fetal ventral mesencephalon, maintain the potential to differentiate into dopaminergic neurons after expansion in vitro. Stem Cells 2006, 24(6):1583-1593.
41. Clarkson E.D., Zawada W.M., Adams F.S., Bell K.P., Freed C.R. Strands of embryonic mesencephalic tissue show greater dopamine neuron survival and better behavioral improvement than cell suspensions after transplantation in parkinsonian rats. Brain Research 1998, 806(1):60-68.
42. Clarkson E.D., Zawada W.M., Bell K.P., Esplen J.E., Choi P.K., Heidenreich K.A., et al. IGF-I and bFGF improve dopamine neuron survival and behavioral outcome in parkinsonian rats receiving cultured human fetal tissue strands. Experimental Neurology 2001, 168(1):183-191.
43. Conti L., Pollard S.M., Gorba T., Reitano E., Toselli M., Biella G., et al. Niche-independent symmetrical self-renewal of a mammalian tissue stem cell. PLoS Biology 2005, 3(9):e283.
44. Correia A.S., Anisimov S.V., Roybon L., Li J.Y., Brundin P. Fibroblast growth factor-20 increases the yield of midbrain dopaminergic neurons derived from human embryonic stem cells. Frontiers in Neuroanatomy 2007, 1:4.
45. Cubo E., Gracies J.M., Benabou R., Olanow C.W., Raman R., Leurgans S., et al. Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Archives of Neurology 2001, 58(9):1379-1382.
46. DeFrancesco L. Fits and starts for Geron. Nature Biotechnology 2009, 27:877.
47. Duan W.M., Widner H., Brundin P. Temporal pattern of host responses against intrastriatal grafts of syngeneic, allogeneic or xenogeneic embryonic neuronal tissue in rats. Experimental Brain Research 1995, 104(2):227-242.
48. Evans M.J., Kaufman M.H. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981, 292(5819):154-156.
49. Foltynie T., Brayne C., Barker R.A. The heterogeneity of idiopathic Parkinson's disease. Journal of Neurology 2002, 249(2):138-145.
50. Freed C.R., Breeze R.E., Rosenberg N.L., Schneck S.A., Kriek E., Qi J.X., et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. New England Journal of Medicine 1992, 327(22):1549-1555.
51. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. New England Journal of Medicine 2001, 344(10):710-719.
52. Freeman T.F., Brundin P. Important aspects of surgical methodology for transplantation in Parkinson's disease. Restorative therapies in Parkinson's disease (pp. 131-165). 2006, Springer Science Business Media B.V, Berlin. P. Brundin, C.W. Olanow (Eds.).
53. Freeman T.B., Olanow C.W., Hauser R.A., Nauert G.M., Smith D.A., Borlongan C.V., et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Annals of Neurology 1995, 38(3):379-388.
54. Fricker R.A., Carpenter M.K., Winkler C., Greco C., Gates M.A., Bjorklund A. Site-specific migration and neuronal differentiation of human neural progenitor cells after transplantation in the adult rat brain. Journal of Neuroscience 1999, 19(14):5990-6005.
55. Frodl E.M., Duan W.M., Sauer H., Kupsch A., Brundin P. Human embryonic dopamine neurons xenografted to the rat: Effects of cryopreservation and varying regional source of donor cells on transplant survival, morphology and function. Brain Research 1994, 647(2):286-298.
56. Gage F.H. Mammalian neural stem cells. Science 2000, 287(5457):1433-1438.
57. Grasbon-Frodl E.M., Andersson A., Brundin P. Lazaroid treatment prevents death of cultured rat embryonic mesencephalic neurons following glutathione depletion. Journal of Neurochemistry 1996, 67(4):1653-1660.
58. Grealish S., Jonsson M.E., Li M., Kirik D., Bjorklund A., Thompson L.H. The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease. Brain 2010, 133(Pt 2):482-495.
59. Greffard S., Verny M., Bonnet A.M., Seilhean D., Hauw J.J., Duyckaerts C. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death. Neurobiology of Aging 2010, 31(1):99-103.
60. Gustavii B. Fetal brain transplantation for Parkinson's disease: Technique for obtaining donor tissue. Lancet 1989, 1(8637):565.
61. Hagell P., Brundin P. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. Journal of Neuropathology and Experimental Neurology 2001, 60(8):741-752.
62. Hagell P., Cenci M.A. Dyskinesias and dopamine cell replacement in Parkinson's disease: A clinical perspective. Brain Research Bulletin 2005, 68(1-2):4-15.
63. Hagell P., Piccini P., Bjorklund A., Brundin P., Rehncrona S., Widner H., et al. Dyskinesias following neural transplantation in Parkinson's disease. Nature Neuroscience 2002, 5(7):627-628.
64. Hagell P., Schrag A., Piccini P., Jahanshahi M., Brown R., Rehncrona S., et al. Sequential bilateral transplantation in Parkinson's disease: Effects of the second graft. Brain 1999, 122(Pt 6):1121-1132.
65. Hauser R.A., Freeman T.B., Snow B.J., Nauert M., Gauger L., Kordower J.H., et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Archives of Neurology 1999, 56(2):179-187.
66. Hebsgaard J.B., Nelander J., Sabelstrom H., Jonsson M.E., Stott S., Parmar M. Dopamine neuron precursors within the developing human mesencephalon show radial glial characteristics. Glia 2009, 57(15):1648-1658.
67. Hedlund E., Pruszak J., Ferree A., Vinuela A., Hong S., Isacson O., et al. Selection of embryonic stem cell-derived enhanced green fluorescent protein-positive dopamine neurons using the tyrosine hydroxylase promoter is confounded by reporter gene expression in immature cell populations. Stem Cells 2007, 25(5):1126-1135.
68. Hedlund E., Pruszak J., Lardaro T., Ludwig W., Vinuela A., Kim K.S., et al. Embryonic stem cell-derived Pitx3-enhanced green fluorescent protein midbrain dopamine neurons survive enrichment by fluorescence-activated cell sorting and function in an animal model of Parkinson's disease. Stem Cells 2008, 26(6):1526-1536.
69. Hong S., Kang U.J., Isacson O., Kim K.S. Neural precursors derived from human embryonic stem cells maintain long-term proliferation without losing the potential to differentiate into all three neural lineages, including dopaminergic neurons. Journal of Neurochemistry 2008, 104(2):316-324.
70. Honig H., Antonini A., Martinez-Martin P., Forgacs I., Faye G.C., Fox T., et al. Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life. Movement Disorder 2009, 24(10):1468-1474.
71. Hu B.Y., Weick J.P., Yu J., Ma L.X., Zhang X.Q., Thomson J.A., et al. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(9):4335-4340.
72. Hughes A.J., Daniel S.E., Ben-Shlomo Y., Lees A.J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002, 125(Pt 4):861-870.
73. Hutchinson M., Gurney S., Newson R. GDNF in Parkinson disease: An object lesson in the tyranny of type II. Journal of Neuroscience Methods 2007, 163(2):190-192.
74. Iacovitti L., Donaldson A.E., Marshall C.E., Suon S., Yang M. A protocol for the differentiation of human embryonic stem cells into dopaminergic neurons using only chemically defined human additives: Studies in vitro and in vivo. Brain Research 2007, 1127(1):19-25.
75. Joksimovic M., Yun B.A., Kittappa R., Anderegg A.M., Chang W.W., Taketo M.M., et al. Wnt antagonism of Shh facilitates midbrain floor plate neurogenesis. Nature Neuroscience 2009, 12(2):125-131.
76. Kaji K., Norrby K., Paca A., Mileikovsky M., Mohseni P., Woltjen K. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009, 458(7239):771-775.
77. Kele J., Simplicio N., Ferri A.L., Mira H., Guillemot F., Arenas E., et al. Neurogenin 2 is required for the development of ventral midbrain dopaminergic neurons. Development 2006, 133(3):495-505.
78. Kintner C. Neurogenesis in embryos and in adult neural stem cells. Journal of Neuroscience 2002, 22(3):639-643.
79. Ko J.Y., Park C.H., Koh H.C., Cho Y.H., Kyhm J.H., Kim Y.S., et al. Human embryonic stem cell-derived neural precursors as a continuous, stable, and on-demand source for human dopamine neurons. Journal of Neurochemistry 2007, 103(4):1417-1429.
80. Kordower J.H., Chu Y., Hauser R.A., Freeman T.B., Olanow C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nature Medicine 2008, 14(5):504-506.
81. Kordower J.H., Chu Y., Hauser R.A., Olanow C.W., Freeman T.B. Transplanted dopaminergic neurons develop PD pathologic changes: A second case report. Movement Disorder 2008, 23(16):2303-2306.
82. Kordower J.H., Rosenstein J.M., Collier T.J., Burke M.A., Chen E.Y., Li J.M., et al. Functional fetal nigral grafts in a patient with Parkinson's disease: Chemoanatomic, ultrastructural, and metabolic studies. Journal of Comparative Neurology 1996, 370(2):203-230.
83. Laguna Goya R., Tyers P., Barker R.A. The search for a curative cell therapy in Parkinson's disease. Journal of the Neurological Sciences 2008, 265(1-2):32-42.
84. Lane E.L., Brundin P., Cenci M.A. Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease. Neurobiology of Disease 2009, 35(1):42-51.
85. Lane E.L., Soulet D., Vercammen L., Cenci M.A., Brundin P. Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease. Neurobiology of Disease 2008, 32(2):220-228.
86. Lane E.L., Vercammen L., Cenci M.A., Brundin P. Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats. Experimental Neurology 2009, 219(1):355-358.
87. Lane E.L., Winkler C., Brundin P., Cenci M.A. The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat. Neurobiology of Disease 2006, 22(2):334-345.
88. Lang A.E., Obeso J.A. Challenges in Parkinson's disease: Restoration of the nigrostriatal dopamine system is not enough. Lancet Neurology 2004, 3(5):309-316.
89. Laywell E.D., Rakic P., Kukekov V.G., Holland E.C., Steindler D.A. Identification of a multipotent astrocytic stem cell in the immature and adult mouse brain. Proceedings of the National Academy of Sciences of the United States of America 2000, 97(25):13883-13888.
90. Lee H.S., Bae E.J., Yi S.H., Shim J.W., Jo A.Y., Kang J.S., et al. Foxa2 and Nurr1 synergistically yield A9 nigral dopamine neurons exhibiting improved differentiation, function, and cell survival. Stem Cells 2010, 28(3):501-512.
91. Lewis S.J., Caldwell M.A., Barker R.A. Modern therapeutic approaches in Parkinson's disease. Expert Reviews in Molecular Medicine 2003, 5(10):1-20.
92. Lewis S.J., Foltynie T., Blackwell A.D., Robbins T.W., Owen A.M., Barker R.A. Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. Journal of Neurology, Neurosurgery and Psychiatry 2005, 76(3):343-348.
93. Li J.Y., Christophersen N.S., Hall V., Soulet D., Brundin P. Critical issues of clinical human embryonic stem cell therapy for brain repair. Trends in Neurosciences 2008, 31(3):146-153.
94. Li J.Y., Englund E., Holton J.L., Soulet D., Hagell P., Lees A.J., et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nature Medicine 2008, 14(5):501-503.
95. Li J.Y., Englund E., Widner H., Rehncrona S., Bjorklund A., Lindvall O., et al. Characterization of Lewy body pathology in 12- and 16-year old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Movement Disorder 2010, 25(8):1091-1096.
96. Lindvall O., Brundin P., Widner H., Rehncrona S., Gustavii B., Frackowiak R., et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990, 247(4942):574-577.
97. Lindvall O., Rehncrona S., Brundin P., Gustavii B., Astedt B., Widner H., et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Archives of Neurology 1989, 46(6):615-631.
98. Lindvall O., Sawle G., Widner H., Rothwell J.C., Bjorklund A., Brooks D., et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Annals of Neurology 1994, 35(2):172-180.
99. Luquin M.R., Scipioni O., Vaamonde J., Gershanik O., Obeso J.A. Levodopa-induced dyskinesias in Parkinson's disease: Clinical and pharmacological classification. Movement Disorder 1992, 7(2):117-124.
100. Lyssiotis C.A., Foreman R.K., Staerk J., Garcia M., Mathur D., Markoulaki S., et al. Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(22):8912-8917.
101. Ma Y., Feigin A., Dhawan V., Fukuda M., Shi Q., Greene P., et al. Dyskinesia after fetal cell transplantation for parkinsonism: A PET study. Annals of Neurology 2002, 52(5):628-634.
102. Ma Y., Tang C., Chaly T., Greene P., Breeze R., Fahn S., et al. Dopamine cell implantation in Parkinson's disease: Long-term clinical and (18)F-FDOPA PET outcomes. Journal of Nuclear Medicine 2010, 51(1):7-15.
103. Madrazo I., Leon V., Torres C., Aguilera M.C., Varela G., Alvarez F., et al. Transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson's disease. New England Journal of Medicine 1988, 318(1):51.
104. Maitra A., Arking D.E., Shivapurkar N., Ikeda M., Stastny V., Kassauei K., et al. Genomic alterations in cultured human embryonic stem cells. Nature Genetics 2005, 37(10):1099-1103.
105. Martin G.R. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proceedings of the National Academy of Sciences of the United States of America 1981, 78(12):7634-7638.
106. Matcham J., McDermott M.P., Lang A.E. GDNF in Parkinson's disease: The perils of post-hoc power. Journal of Neuroscience Methods 2007, 163(2):193-196.
107. Maxwell S.L., Ho H.Y., Kuehner E., Zhao S., Li M. Pitx3 regulates tyrosine hydroxylase expression in the substantia nigra and identifies a subgroup of mesencephalic dopaminergic progenitor neurons during mouse development. Developmental Biology 2005, 282(2):467-479.
108. Mendez I., Dagher A., Hong M., Hebb A., Gaudet P., Law A., et al. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. Journal of Neurosurgery 2000, 92(5):863-869.
109. Mendez I., Vinuela A., Astradsson A., Mukhida K., Hallett P., Robertson H., et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nature Medicine 2008, 14(5):507-509.
110. Nelander J., Hebsgaard J.B., Parmar M. Organization of the human embryonic ventral mesencephalon. Gene Expression Patterns 2009, 9(8):555-561.
111. Nicholas C.R., Gaur M., Wang S., Pera R.A., Leavitt A.D. A method for single-cell sorting and expansion of genetically modified human embryonic stem cells. Stem Cells and Development 2007, 16(1):109-117.
112. Nichols J., Smith A. Naive and primed pluripotent states. Cell Stem Cell 2009, 4(6):487-492.
113. Nikkhah G., Eberhard J., Olsson M., Bjorklund A. Preservation of fetal ventral mesencephalic cells by cool storage: In-vitro viability and TH-positive neuron survival after microtransplantation to the striatum. Brain Research 1995, 687(1-2):22-34.
114. Nishikawa S., Goldstein R.A., Nierras C.R. The promise of human induced pluripotent stem cells for research and therapy. Nature Reviews Molecular Cell Biology 2008, 9(9):725-729.
115. Okita K., Hong H., Takahashi K., Yamanaka S. Generation of mouse-induced pluripotent stem cells with plasmid vectors. Nature Protocols 2010, 5(3):418-428.
116. Olanow C.W., Freeman T., Kordower J. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. New England Journal of Medicine 2001, 345(2):146. author reply 147.
117. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Annals of Neurology 2003, 54(3):403-414.
118. Olanow C.W., Kordower J.H., Lang A.E., Obeso J.A. Dopaminergic transplantation for Parkinson's disease: Current status and future prospects. Annals of Neurology 2009, 66(5):591-596.
119. Ono Y., Nakatani T., Sakamoto Y., Mizuhara E., Minaki Y., Kumai M., et al. Differences in neurogenic potential in floor plate cells along an anteroposterior location: Midbrain dopaminergic neurons originate from mesencephalic floor plate cells. Development 2007, 134(17):3213-3225.
120. Ostenfeld T., Joly E., Tai Y.T., Peters A., Caldwell M., Jauniaux E., et al. Regional specification of rodent and human neurospheres. Brain Research Developmental Brain Research 2002, 134(1-2):43-55.
121. Palmer T.D., Markakis E.A., Willhoite A.R., Safar F., Gage F.H. Fibroblast growth factor-2 activates a latent neurogenic program in neural stem cells from diverse regions of the adult CNS. Journal of Neuroscience 1999, 19(19):8487-8497.
122. Parish C.L., Castelo-Branco G., Rawal N., Tonnesen J., Sorensen A.T., Salto C., et al. Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. Journal of Clinical Investigation 2008, 118(1):149-160.
123. Park C.H., Lee S.H. Efficient generation of dopamine neurons from human embryonic stem cells. Methods in Molecular Biology 2007, 407:311-322.
124. Park C.H., Minn Y.K., Lee J.Y., Choi D.H., Chang M.Y., Shim J.W., et al. In vitro and in vivo analyses of human embryonic stem cell-derived dopamine neurons. Journal of Neurochemistry 2005, 92(5):1265-1276.
125. Parmar M., Skogh C., Bjorklund A., Campbell K. Regional specification of neurosphere cultures derived from subregions of the embryonic telencephalon. Molecular and Cellular Neuroscience 2002, 21(4):645-656.
126. Paul G., Christophersen N.S., Raymon H., Kiaer C., Smith R., Brundin P. Tyrosine hydroxylase expression is unstable in a human immortalized mesencephalic cell line - studies in vitro and after intracerebral grafting in vivo. Molecular and Cellular Neuroscience 2007, 34(3):390-399.
127. Perrier A.L., Tabar V., Barberi T., Rubio M.E., Bruses J., Topf N., et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(34):12543-12548.
128. Peschanski M., Defer G., N'Guyen J.P., Ricolfi F., Monfort J.C., Remy P., et al. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 1994, 117(Pt 3):487-499.
129. Petersen A., Hansson O., Emgard M., Brundin P. Grafting of nigral tissue hibernated with tirilazad mesylate and glial cell line-derived neurotrophic factor. Cell Transplantation 2000, 9(5):577-584.
130. Piccini P., Brooks D.J., Bjorklund A., Gunn R.N., Grasby P.M., Rimoldi O., et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nature Neuroscience 1999, 2(12):1137-1140.
131. Piccini P., Lindvall O., Bjorklund A., Brundin P., Hagell P., Ceravolo R., et al. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Annals of Neurology 2000, 48(5):689-695.
132. Piccini P., Pavese N., Hagell P., Reimer J., Bjorklund A., Oertel W.H., et al. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 2005, 128(Pt 12):2977-2986.
133. Placantonakis D.G., Tomishima M.J., Lafaille F., Desbordes S.C., Jia F., Socci N.D., et al. BAC transgenesis in human embryonic stem cells as a novel tool to define the human neural lineage. Stem Cells 2009, 27(3):521-532.
134. Pruszak J., Ludwig W., Blak A., Alavian K., Isacson O. CD15, CD24, and CD29 define a surface biomarker code for neural lineage differentiation of stem cells. Stem Cells 2009, 27(12):2928-2940.
135. Redmond D.E., Leranth C., Spencer D.D., Robbins R., Vollmer T., Kim J.H., et al. Fetal neural graft survival. Lancet 1990, 336(8718):820-822.
136. Reubinoff B.E., Itsykson P., Turetsky T., Pera M.F., Reinhartz E., Itzik A., et al. Neural progenitors from human embryonic stem cells. Nature Biotechnology 2001, 19(12):1134-1140.
137. Reynolds B.A., Tetzlaff W., Weiss S. A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. Journal of Neuroscience 1992, 12(11):4565-4574.
138. Reynolds B.A., Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992, 255(5052):1707-1710.
139. Rosser A.E., Tyers P., Dunnett S.B. The morphological development of neurons derived from EGF- and FGF-2-driven human CNS precursors depends on their site of integration in the neonatal rat brain. European Journal of Neuroscience 2000, 12(7):2405-2413.
140. Roybon L., Hjalt T., Christophersen N.S., Li J.Y., Brundin P. Effects on differentiation of embryonic ventral midbrain progenitors by Lmx1a, Msx1, Ngn2, and Pitx3. Journal of Neuroscience 2008, 28(14):3644-3656.
141. Sareen D., McMillan E., Ebert A.D., Shelley B.C., Johnson J.A., Meisner L.F., et al. Chromosome 7 and 19 trisomy in cultured human neural progenitor cells. PLoS One 2009, 4(10):e7630.
142. Sauer H., Brundin P. Effects of cool storage on survival and function of intrastriatal ventral mesencephalic grafts. Restorative Neurology and Neuroscience 1991, 2:123-135.
143. Sayles M., Jain M., Barker R.A. The cellular repair of the brain in Parkinson's disease-past, present and future. Transplant Immunology 2004, 12(3-4):321-342.
144. Schaff E.A. Mifepristone: Ten years later. Contraception 2010, 81(1):1-7.
145. Soderstrom K.E., Meredith G., Freeman T.B., McGuire S.O., Collier T.J., Sortwell C.E., et al. The synaptic impact of the host immune response in a parkinsonian allograft rat model: Influence on graft-derived aberrant behaviors. Neurobiology of Disease 2008, 32(2):229-242.
146. Soldner F., Hockemeyer D., Beard C., Gao Q., Bell G.W., Cook E.G., et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009, 136(5):964-977.
147. Sommer U., Hummel T., Cormann K., Mueller A., Frasnelli J., Kropp J., et al. Detection of presymptomatic Parkinson's disease: Combining smell tests, transcranial sonography, and SPECT. Movement Disorder 2004, 19(10):1196-1202.
148. Spencer D.D., Robbins R.J., Naftolin F., Marek K.L., Vollmer T., Leranth C., et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. New England Journal of Medicine 1992, 327(22):1541-1548.
149. Stadtfeld M., Nagaya M., Utikal J., Weir G., Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science 2008, 322(5903):945-949.
150. Steece-Collier K., Soderstrom K.E., Collier T.J., Sortwell C.E., Maries-Lad E. Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats. Journal of Comparative Neurology 2009, 515(1):15-30.
151. Studer L., Csete M., Lee S.H., Kabbani N., Walikonis J., Wold B., et al. Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowered oxygen. Journal of Neuroscience 2000, 20(19):7377-7383.
152. Sun Y., Pollard S., Conti L., Toselli M., Biella G., Parkin G., et al. Long-term tripotent differentiation capacity of human neural stem (NS) cells in adherent culture. Molecular and Cellular Neuroscience 2008, 38(2):245-258.
153. Suslov O.N., Kukekov V.G., Ignatova T.N., Steindler D.A. Neural stem cell heterogeneity demonstrated by molecular phenotyping of clonal neurospheres. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(22):14506-14511.
154. Swistowski A., Peng J., Han Y., Swistowska A.M., Rao M.S., Zeng X. Xeno-free defined conditions for culture of human embryonic stem cells, neural stem cells and dopaminergic neurons derived from them. PLoS One 2009, 4(7):e6233.
155. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131(5):861-872.
156. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126(4):663-676.
157. Tesar P.J., Chenoweth J.G., Brook F.A., Davies T.J., Evans E.P., Mack D.L., et al. New cell lines from mouse epiblast share defining features with human embryonic stem cells. Nature 2007, 448(7150):196-199.
158. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., Waknitz M.A., Swiergiel J.J., Marshall V.S., et al. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282(5391):1145-1147.
159. Unger C., Skottman H., Blomberg P., Dilber M.S., Hovatta O. Good manufacturing practice and clinical-grade human embryonic stem cell lines. Human Molecular Genetics 2008, 17(R1):R48-R53.
160. Vierbuchen T., Ostermeier A., Pang Z.P., Kokubu Y., Sudhof T.C., Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010, 463(7284):1035-1041.
161. Wenning G.K., Odin P., Morrish P., Rehncrona S., Widner H., Brundin P., et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Annals of Neurology 1997, 42(1):95-107.
162. Wernig M., Zhao J.P., Pruszak J., Hedlund E., Fu D., Soldner F., et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(15):5856-5861.
163. Widner H. NIH neural transplantation funding. Science 1994, 263(5148):737.
164. Widner H., Brundin P. Immunological aspects of grafting in the mammalian central nervous system. A review and speculative synthesis. Brain Research 1988, 472(3):287-324.
165. Widner H., Tetrud J., Rehncrona S., Snow B., Brundin P., Gustavii B., et al. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). New England Journal of Medicine 1992, 327(22):1556-1563.
166. Williams-Gray C.H., Evans J.R., Goris A., Foltynie T., Ban M., Robbins T.W., et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009, 132(Pt 11):2958-2969.
167. Woltjen K., Michael I.P., Mohseni P., Desai R., Mileikovsky M., Hamalainen R., et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009, 458(7239):766-770.
168. Yan J., Studer L., McKay R.D. Ascorbic acid increases the yield of dopaminergic neurons derived from basic fibroblast growth factor expanded mesencephalic precursors. Journal of Neurochemistry 2001, 76(1):307-311.
169. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318(5858):1917-1920.
170. Zeng X., Cai J., Chen J., Luo Y., You Z.B., Fotter E., et al. Dopaminergic differentiation of human embryonic stem cells. Stem Cells 2004, 22(6):925-940.
171. Zhou Q., Brown J., Kanarek A., Rajagopal J., Melton D.A. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 2008, 455(7213):627-632.
172. Zigmond M.J. Triggering endogenous neuroprotective mechanisms in Parkinson's disease: Studies with a cellular model. Journal of Neural Transmission 2006, 70(Suppl):439-442.